Abstract 1787P
Background
The potential for PSMA PET-directed treatment decisions to improve outcomes in mHSPC remains unknown. We explored first response and progression/relapse patterns in newly diagnosed PSMA PET-detected mHSPC and correlated PET-directed staging with clinical outcomes.
Methods
184 patients with baseline PSMA PET were retrospectively reviewed. Patients were sub-grouped into oligometastatic disease (OMD) and polymetastatic disease (PMD) utilising the STAMPEDE2 trial definition. Data on patient demographics, treatment, and imaging findings were collected. Treatment response was assessed using PSA nadir and radiological imaging at six months from PSA nadir. Disease progression/relapse was assessed using PCWG3, RECIST 1.1 and PERCIST 1.0 criteria. Kaplan Meier method estimated median time to radiographic progression-free survival (rPFS).
Results
Median age was 69 years. All patients had androgen deprivation therapy. 161/184 (88%) had additional systemic therapies. 99/184 (54%) had OMD and 85/184 (46%) had PMD. Prostate radiotherapy was given in 76/99 (77%) OMD patients and 47/85 (55%) PMD patients. Median time to PSA nadir in OMD and PMD was 10 months (range 1 to 29) and 8 months (range 1 to 36), respectively. Response images were available in 35/99 (35%) OMD patients and 39/85 (46%) PMD patients. Median time to radiological response in OMD and PMD was 10 months (range 2 to 58) and 9 months (range 2 to 36), respectively. Radiological progression in OMD most frequently occurred with new sites of disease (73%). Median rPFS was 53 months (95% CI 40, undefined) in OMD patients and 35 months (95% CI 22, 43) in PMD patients. Table: 1787P
Radiological response and progression/relapse in OMD and PMD
OMD (N= 99) | PMD (N= 85) | |
Radiological response | n= 35 (35%) | n= 39 (46%) |
Complete Response | 12 (34%) | 7 (18%) |
Partial Response | 21 (60%) | 29 (74%) |
Stable Disease | 1 (3%) | 2 (5%) |
Not evaluable | 1 (3%) | 1 (3%) |
Site of Radiological progression/relapse compared with baseline disease | n= 22 (22%) | n= 37 (43%) |
Same sites | 5 (23%) | 18 (49%) |
Different sites | 10 (45%) | 9 (24%) |
Mixed sites | 6 (27%) | 10 (27%) |
Not evaluable | 1 (5%) | 0 (0%) |
Conclusions
PSMA PET-guided outcomes were similar to series with conventional staging, suggesting PET-directed therapy choices might not significantly influence time to progression. This will be further investigated in the forthcoming STAMPEDE2 trial.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
H. Abdel-Aty.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1807P - Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status
Presenter: Nobuaki Matsubara
Session: Poster session 14
1808P - Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m<sup>2</sup>) versus every 3 weeks (25 mg/m<sup>2</sup>) in the CABASTY phase III trial
Presenter: Stephane Oudard
Session: Poster session 14
1809P - Dynamics of plasma tumour DNA and copy number alterations in advanced metastatic castration-resistant prostate cancer (mCRPC) patients treated with cabazitaxel: A prospective biomarker trial
Presenter: Nicole Brighi
Session: Poster session 14
1810P - Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer
Presenter: Michael Morris
Session: Poster session 14
1811P - Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase III (TALAPRO-2) study
Presenter: Andre Fay
Session: Poster session 14
1813P - Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results
Presenter: Andrew Laccetti
Session: Poster session 14
1814P - First real-life data on [177Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in early access in France
Presenter: Anne-Laure Giraudet
Session: Poster session 14
1815P - Emergent circulating tumor DNA (ctDNA) variants and ctDNA burden dynamics with potential associations with talazoparib antitumor activity in TALAPRO-1
Presenter: Elena Castro
Session: Poster session 14